Revlimid maintenance therapy passes reimbursement review

30 June 2022 - Revlimid maintenance therapy to treat multiple myeloma passed the health insurance review agency’s reimbursement review four ...

Read more →

Reimbursement price of GERD drug Fexclu finalised at $0.73

29 June 2022 - The Ministry of Health and Welfare’s health insurance policy committee set the reimbursement price of Fexclu ...

Read more →

HIRA reviews reimbursing antidiabetic combo therapies

15 June 2022 - HIRA has been analysing how new reimbursements for anti-diabetic combination therapies mixing oral SGLT-2 and DPP-4 ...

Read more →

Janssen’s psoriatic arthritis drug Tremfya gets insurance coverage

26 May 2022 - Janssen Korea said that the Ministry of Health and Welfare would begin to reimburse Tremfya, its ...

Read more →

BMS’ Sprycel reimbursement criteria to be broadened for paediatric Philadelphia chromosome positive ALL

19 May 2022 - The state health insurance review agency said it would broaden the reimbursement criteria for Sprycel (dasatinib), ...

Read more →

Korea clears permit for Samsung Bioepis’ Lucentis biosimilar after US

16 May 2022 - Samsung Bioepis received marketing approval for Amelivu (ranibizumab), a biosimilar referencing Lucentis to treat various eye ...

Read more →

Digital health devices must prove a benefit to get reimbursement

13 May 2022 - Digital health care companies should prove that their devices can improve the quality of patient care ...

Read more →

Fertility drug Rekovelle gets reimbursable in combo with hMG

10 May 2022 - Ferring’s Rekovelle (follitropin delta), a treatment to promote egg production in ovaries, became reimbursable when used ...

Read more →

HIRA unveils detailed reimbursement criteria for Olumiant, Rinvoq

10 May 2022 - Lilly’s Olumiant (baricitinib) and Abbvie’s Rinvoq (upadacitinib) got health insurance benefits starting from May 1 to ...

Read more →

Prices of Tecentriq, Avastin go down due to broader insurance benefits

2 May 2022 - The Government granted health insurance benefits to the combination therapy of Tecentriq and Avastin to treat ...

Read more →

Gilead Science’s hepatitis B drug Vemlidy gets expanded insurance benefit

2 May 2022 - Gilead Science Korea said its hepatitis B treatment Vemlidy (tenofovir alafenamide) started receiving expanded health insurance ...

Read more →

Is it best to remove insurance benefits from drugs prescribed in bribery?

25 April 2022 - The Ministry of Health and Welfare’s Health Insurance Policy Review Committee is scheduled to hold a ...

Read more →

When will SMA oral drug Evrysdi get insurance benefits?

14 April 2022 - Roche’s new spinal muscular atrophy oral treatment Evrysdi (risdiplam) proved the benefit of convenience and cost ...

Read more →

Pfizer’s ALK targeted therapy Lorviqua passes reimbursement review

8 April 2022 - Pfizer’s Lorviqua (lorlatinib), a third generation anaplastic lymphoma kinase (ALK) targeted therapy, passed the review for ...

Read more →

BeiGene’s Brukinsa quickly passes HIRA’s reimbursement review

7 April 2022 - BeiGene’s Brukinsa (zanubrutinib), a next-generation BTK inhibitor, passed the Health Insurance Review and Assessment Service’s Cancer ...

Read more →